<DOC>
	<DOCNO>NCT02088645</DOCNO>
	<brief_summary>The purpose study determine use 177Lu-PP-F11N imaging therapy patient advance medullary thyroid carcinoma ( MTC ) . 177Lu-PP-F11N gastrin analogon , bind cholecystokinin-2 receptor . This receptors show overexpression 90 % medullary thyroid carcinoma . In pilot ( phase 0 ) study correlate tumour detection rate surgery histology ( proof concept study ) . Furthermore , kidney protection dosimetry study perform order determine kidney protection protocol start activity dose escalation study follow , dose escalation ( phase I ) study . In phase I study determinate maximum tolerate dose 177Lu-PP-F11N patient MTC . Furthermore , correlation tumour radiation dose treatment response well organ radiation dose maximal tolerate dose perform order allow prospective individual patient tailor therapy planning .</brief_summary>
	<brief_title>177Lu-PP-F11N Receptor Targeted Therapy Imaging Metastatic Thyroid Cancer .</brief_title>
	<detailed_description />
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Neuroendocrine</mesh_term>
	<mesh_term>Cholecystokinin</mesh_term>
	<mesh_term>Gastrins</mesh_term>
	<criteria>Phase 0 study Advanced MTC elevate level calcitonin ( &gt; 100 pg/ml ) and/or calcitonindoubling time &lt; 24 month total thyroidectomy Age &gt; 18 year Informed consent Phase I study Diagnostic , contrast medium enhance CT scan neck/thorax/abdomen , old 4 week Advanced MTC elevate level calcitonin ( &gt; 100 pg/ml ) and/or calcitonindoubling time &lt; 24 month total thyroidectomy Age &gt; 18 Years Informed consent Curative surgical therapy possible Phase 0 study Medication Vandetanib 3 week study study Renal failure ( calculated glomerular filtration rate ( GFR ) &lt; 60 ml/min per 1.73 m2 body surface ) . Bone marrow failure ( thrombocytes &lt; 70 000/μl , leucocytes &lt; 2 500/μl , hemoglobin &lt; 8 g/dl ) . Pregnancy breast feeding Knows allergic reaction Physiogel gelatine product Known , serious side reaction case former application pentagastrin Active , second malignancy oder remission second malignancy &lt; 5 year Phase I study Medication Vandetanib 3 week study study Renal failure ( calculate GFR &lt; 70 ml/min per 1.73 m2 body surface ) . Bone marrow failure ( thrombocytes &lt; 100 000/μl , leucocytes &lt; 3 000/μl , hemoglobin &lt; 10 g/dl ) . Pregnancy breast feed Known allergic reaction Physiogel gelatine product Known , serious side reaction case former application pentagastrin Active , second malignancy oder remission second malignancy &lt; 5 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Calcitonin</keyword>
	<keyword>Medullary thyroid carcinoma</keyword>
	<keyword>Peptide receptor radionuclide therapy</keyword>
	<keyword>Gastrin</keyword>
	<keyword>Cholecystokinin-2 receptor</keyword>
</DOC>